Medline's bed recall remedy plan shows how device harm data becomes continued-use guidance
Medline's updated repair-and-replace programme follows seven deaths and 35 serious injuries. For PV teams, the case is a lesson in turning harm reports into actionable advice.
What happened
On 13 November 2026, FDA's MedWatch recall channel carried an update from Medline on its repair and replace programme for recalled beds, rails, mattresses and accessories. The company has updated its guidance on continued use and on remedies for all of its branded beds and accessories. The recall concerns fire and entrapment risks, which the notice links to seven deaths and 35 serious injuries.
The record is short. It does not set out what the repair or replacement involves, how long it will take, how many units are affected, or which interim precautions Medline advises while products stay in service. Those details sit in the underlying notice, and readers should consult it directly rather than rely on summaries. What the record does establish is the scope (all Medline-branded beds and accessories), the two hazards (fire and entrapment) and the severity of the reported harm.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources this analysis is based on
- Medline details repair and replace programme for recalled beds, rails, mattresses and accessories FDA MedWatch · Fri 13 Nov 2026
- PRAC publishes final EU-language translations of phenobarbital product information in targeted signal procedure EMA · PRAC · Fri 13 Nov 2026
- EMA page on veterinary signal management details phenobarbital review and updated MAH templates EMA · PRAC · Fri 13 Nov 2026
- EMA publishes draft veterinary PV guideline listing medically important VeDDRA terms EMA · Fri 13 Nov 2026
- EMA opens consultation on medically important VeDDRA terms list for veterinary pharmacovigilance EMA · Fri 13 Nov 2026
- FTC sues to block Covetrus's $3.5bn acquisition of veterinary distributor MWI FTC · Fri 13 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
FTC's bid to block Covetrus-MWI puts veterinary distribution, and PV information flow, in focus
The US suit against a $3.5bn merger of the two largest vet distributors is an antitrust case, but animal-health PV teams should check how safety information moves through the channel.
Vercise DBS instruction recall: why IFU corrections matter to trial teams
Health Canada's Type II recall of Vercise clinician programmer instructions is narrow, but it shows how a labelling correction can ripple into protocols, training and site files.
Denmark's Voltabak shortage to mid-May 2027 shows how fragile single-source supply is
DKMA's updated notice on Laboratoires Thea's diclofenac eye drops, with the Methergin withdrawal and estradiol patch notices, shows how Denmark manages supply failures.